On January 11, 2024, Dyne Therapeutics, Inc., a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, announced the closing of an underwritten public offering of 19,722,500 shares of its common stock at a public offering price of $17.50 per share, which includes 2,572,500 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to Dyne from the offering were approximately $345.1 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. Morgan Stanley, J.P. Morgan, Jefferies and Stifel acted as joint book-running managers for the offering. Oppenheimer & Co. and Raymond James acted as co-managers for the offering.

The WilmerHale team representing Dyne Therapeutics included Stuart Falber, Scott Lunin, William Hall, Michelle Sidle and Giuliana Green.